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Abstract 
Background and purpose 
Transcription factor MafB belongs to the large Maf family that regulates 
target genes by binding into Maf recognition element (MARE) in the 
promoter region. In hematopoietic system, MafB is specifically expressed 
in monocytes and macrophages, and affects proliferation and 
differentiation of macrophages. Previous studies suggested MafB functions 
in physiology of macrophages and may play a role in macrophage related-
diseases.  
C1q, the first subcomponent of the classical complement pathway, is 
the receptor of apoptotic cells involved in efferocytosis of macrophages. 
The deficiency of C1q in human and mouse macrophages leads to the 
development of systemic lupus erythematosus (SLE)-like disease because 
of the failure of efferocytosis. However, molecular mechanism of C1q 
regulation is largely unknown. 
Nuclear receptors are transcription factors that are involved in the 
metabolic and immune activities of macrophages. Liver X receptors (LXR) 
promotes the apoptotic cell clearance to suppress inflammatory pathways. 
Deficiency of RXRα, PPARγ or PPARδ induced autoimmune kidney 
diseases. LXR/RXR has been shown to directly regulate the expression of 
Mafb in macrophages. However, there is no report on MafB function in 
efferocytosis and development of autoimmune disease.  
 In this study, I aimed to clarify the role of MafB in efferocytosis and its 
connection with autoimmune diseases by using Mafb-deficient mice. 
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Materials and methods 
To demonstrate whether MafB deficient mice develop autoimmune 
diseases, I analyzed the serum levels of auto-antibodies and the 
accumulation of immune complex in glomeruli of kidney. Then, I evaluated 
glomerulonephritis and the urine protein. Next, I evaluated the 
phagocytosis of Mafb-deficient macrophages using CellTracker or pHrodo-
labelled apoptotic cells. To examine the regulation of C1q by MafB, I 
checked the expression of C1q in WT or Mafb-/- macrophages using qPCR, 
Western blot analysis, and hemolysis assay; and performed promoter 
analysis. To clarify whether MafB promotes the efferocytosis via C1q 
regulation, I rescued the efferocytosis of Mafb-deficient macrophages by 
adding the serum containing C1q protein and checking phagocytosis by 
FACS analysis. To clarify whether PPARδ is upstream regulator of MafB, I 
induced PPARδ expression in macrophages to check expression of Mafb, 
and then performed promoter analysis. To determine whether MafB was 
involved in PPARδ - C1q axis, I induced PPARδ in WT and Mafb-/- 
macrophage and checked C1q expression. 
 
Results 
Here I found that Mafb-deficient mice developed autoimmune 
diseases more seriously than WT mice, due to the increase of serum levels 
of auto-antibodies and glomerulonephritis, and the higher urine protein 
level. The Mafb-/- macrophages failed to engulf or bind to fluorescent 
apoptotic cells when I fed fluorescent apoptotic cells to macrophages in 
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vitro and in vivo. These evidences indicated that MafB affects autoimmune 
diseases through efferocytosis process.  
I investigated whether C1q, composed of C1qa, C1qb, and C1qc, was 
the target molecule of MafB in efferocytosis process. My result showed that 
the expression of C1q in macrophages was decreased. C1q levels and C1q 
activity in the classical complement pathway of Mafb-/- mice were reduced. 
Moreover, the expressions of human C1Q genes were reduced in MAFB-
knock down human macrophage THP-1 cells. Promoter analysis data also 
showed in both humans and mice, MafB directly regulates C1q genes 
through the half-MARE sites. The efferocytosis of Mafb-deficient mice was 
rescued by using WT serum containing C1q protein, suggested the 
disruption of efferocytosis in Mafb-/- macrophages is caused by reduction of 
C1q. 
Moreover, I found that PPARδ is the upstream regulator of MafB in 
efferocytosis. One paper showed PPARδ directly regulates C1q. In Mafb-
deficient macrophages, the expression of C1q under PPARδ induction was 
lower than in WT macrophages, indicated MafB is important for the basal 
expression of C1q genes. 
 
Discussion 
For the first time, I demonstrated that MafB is an important factor for the 
expression of C1qa, C1qb, and C1qc, which assemble the C1q protein. 
C1q plays an important role in the development of autoimmune diseases. 
Clinical reports have shown that 90% of C1q-deficient patients have 
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autoimmune diseases. Consistent with these reports, I have observed a 
similar phenotype in Mafb deficient mice. Therefore, it is likely that MafB 
also regulates C1q genes in other species. The knock-down of MAFB in 
human macrophages causes the down-regulation of C1Q genes. Moreover, 
in zebrafish, C1q promoters have half MAREs, and the preliminary result 
of a zebrafish Mafb morpholino oligo injection showed a reduction in 
zebrafish C1q gene expression (data not shown). The origin of the classical 
pathway was found in sea lamprey and I also found a half-MARE sequence 
from the 5’ upstream of lamprey C1q-like genes. Therefore, the MafB 
binding site may contribute to evolution from the primitive lectin pathway to 
the classical pathway that supports adaptive immunity. 
 
Conclusion 
The present results indicate that MafB is the primary regulator of C1q 
genes. In addition, MafB has a pivotal role in the efferocytosis and inhibition 
of autoimmune disease through the regulation of C1q genes.  
